emerging glp-1 gip obesity treatments 2025 Market Size to Hit USD 66.57 Billion by 2035 The Landscape Of GLP-1 Receptor
Description
Learn what this means for weight loss patients and your options.
Up to 64% of GLP-1 patients discontinue therapy
It's another reason to invest in this exciting medical device stock.
Glucagon-like peptide-1 agonists (GLP-1s) have been in the spotlight as demand has grown to support type 2 diabetes and weight loss
